ArticleScientific reports2025
Choline transporter-like protein 1 in tongue squamous cell carcinoma: implications for cell proliferation and differentiation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SLC Transporter-Mediated Functional Imaging in Cancer Diagnosis.Biomolecules · 2026Review
- Oral cancer in the era of precision medicine: molecular targets and technological innovations.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies have indicated moderate to high choline transporter-like protein 1 (CTL1) expression in colon, pancreatic, breast, lung, and glioma cancers. However, studies on CTL1 in oral squamous cell carcinoma (OSCC), a highly invasive cancer, remain limited. We aimed to investigate the expression and localization of CTL1 in OSCC and its association with cell proliferation. Using in vitro experiments, we evaluated CTL1 expression and localization in the OSCC cell lines HSC-3 and HSC-4 by immunocytochemistry and western blotting. A cell proliferation assay was performed using hemicolinium-3, a choline uptake inhibitor. Using in vivo and ex vivo experiments, we assessed CTL1 expression in rat and human tongue cancer tissues by immunohistochemical and immunofluorescent staining. Here, we show that CTL1 is strongly expressed intracellularly and localized in organelles of HSC-3 and HSC-4 cells. CTL1 significantly accumulated around the nucleus in Ki67-positive cells with proliferative potential, suggesting increased production and transport of CTL1. Conversely, the number of cells in the HC-3 treated group in both HSC-3 and HSC-4 cells decreased. These results suggest that intracellular production of CTL1 is further increased in Ki67-positive cells, and choline uptake may lead to cell proliferation. In vivo and ex vivo experiments revealed high CTL1 expression in tongue cancer, with stronger expression in well-differentiated tumors than that in poorly-differentiated ones. Our study demonstrates that CTL1 is associated with OSCC proliferation and tumor differentiation. These findings suggest that CTL1 may function as a potential marker for tumor differentiation and progression of OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.